Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) have been given an average recommendation of “Buy” by the eight analysts that are currently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $13.14.

Several brokerages have recently commented on TNGX. B. Riley decreased their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research report on Friday, November 8th. Guggenheim dropped their price objective on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th.

Tango Therapeutics Trading Down 9.6 %

NASDAQ TNGX opened at $2.92 on Friday. Tango Therapeutics has a 12 month low of $2.70 and a 12 month high of $13.01. The stock has a market cap of $313.66 million, a price-to-earnings ratio of -2.47 and a beta of 0.81. The company’s 50 day moving average is $3.43 and its two-hundred day moving average is $6.91.

Insider Transactions at Tango Therapeutics

In other Tango Therapeutics news, insider Boxer Capital Management, Llc sold 633,000 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $6.87, for a total transaction of $4,348,710.00. Following the sale, the insider now directly owns 6,690,642 shares of the company’s stock, valued at $45,964,710.54. The trade was a 8.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mace Rothenberg acquired 10,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was bought at an average cost of $3.62 per share, with a total value of $36,200.00. Following the completion of the purchase, the director now directly owns 21,250 shares in the company, valued at approximately $76,925. The trade was a 88.89 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 4,338,000 shares of company stock valued at $18,426,160 in the last ninety days. Corporate insiders own 6.30% of the company’s stock.

Institutional Trading of Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 DIFC Ltd purchased a new position in Tango Therapeutics during the second quarter worth $54,000. Principal Financial Group Inc. purchased a new position in shares of Tango Therapeutics during the 2nd quarter worth about $90,000. Quest Partners LLC boosted its stake in shares of Tango Therapeutics by 1,448.4% during the 3rd quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock worth $84,000 after purchasing an additional 10,182 shares during the period. Quarry LP bought a new position in Tango Therapeutics during the 2nd quarter valued at about $99,000. Finally, SG Americas Securities LLC purchased a new stake in Tango Therapeutics in the 3rd quarter worth about $151,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.